Literature DB >> 16298243

Inhibition of hippocampal function in mild cognitive impairment: targeting the cholinergic hypothesis.

G Grön1, I Brandenburg, A P Wunderlich, M W Riepe.   

Abstract

Mild cognitive impairment (MCI) is a condition with an increased risk of developing Alzheimer's disease. Chief complaint and diagnostic criterion in subjects with mild cognitive impairment is memory failure. We hypothesized that cholinergic malfunction may underlie memory impairment in these subjects and applied a low dosage of an acetylcholinesterase inhibitor and modulator of nicotinic acetylcholine receptors, galantamine (4 mg bid), for 7 days. We used neuropsychological tests to investigate attention, cognitive flexibility, verbal and visual short-term and working memory, susceptibility to interference and episodic memory and functional magnetic resonance imaging to assess spatial navigation both prior to and after treatment. Late episodic learning and delayed recall improved on treatment as did recruitment of the hippocampal region during spatial navigation. Performance in all other neuropsychological measures remained unchanged. We show that an increase of cholinergic neurotransmission in subjects with MCI specifically improves hippocampal function and thus that a cholinergic deficit is functionally relevant in subjects with MCI. Malfunction of the cholinergic system may be tackled pharmacologically via the inhibition of acetylcholinesterase even when the impairment is slight.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16298243     DOI: 10.1016/j.neurobiolaging.2004.12.005

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  22 in total

1.  Cholinergic modulation of hippocampal activity during episodic memory encoding in postmenopausal women: a pilot study.

Authors:  Julie A Dumas; Brenna C McDonald; Andrew J Saykin; Thomas W McAllister; Mary L Hynes; John D West; Paul A Newhouse
Journal:  Menopause       Date:  2010-07       Impact factor: 2.953

2.  Effects of cholinesterase inhibitor on brain activation in Alzheimer's patients measured with functional near-infrared spectroscopy.

Authors:  Florian G Metzger; Ann-Christine Ehlis; Florian B Haeussinger; Andreas J Fallgatter; Katja Hagen
Journal:  Psychopharmacology (Berl)       Date:  2015-09-11       Impact factor: 4.530

Review 3.  Cholinergic modulation of cognition: insights from human pharmacological functional neuroimaging.

Authors:  Paul Bentley; Jon Driver; Raymond J Dolan
Journal:  Prog Neurobiol       Date:  2011-06-17       Impact factor: 11.685

Review 4.  Alzheimer's disease and age-related memory decline (preclinical).

Authors:  Alvin V Terry; Patrick M Callahan; Brandon Hall; Scott J Webster
Journal:  Pharmacol Biochem Behav       Date:  2011-02-24       Impact factor: 3.533

Review 5.  The significance of the cholinergic system in the brain during aging and in Alzheimer's disease.

Authors:  R Schliebs; T Arendt
Journal:  J Neural Transm (Vienna)       Date:  2006-10-13       Impact factor: 3.575

6.  Trimethylaminuria: causes and diagnosis of a socially distressing condition.

Authors:  Richard J Mackay; Christopher J McEntyre; Caroline Henderson; Michael Lever; Peter M George
Journal:  Clin Biochem Rev       Date:  2011-02

7.  Reduction of basal forebrain cholinergic system parallels cognitive impairment in patients at high risk of developing Alzheimer's disease.

Authors:  Michel Grothe; Laszlo Zaborszky; Mercedes Atienza; Eulogio Gil-Neciga; Rafael Rodriguez-Romero; Stefan J Teipel; Katrin Amunts; Aida Suarez-Gonzalez; Jose L Cantero
Journal:  Cereb Cortex       Date:  2009-11-04       Impact factor: 5.357

8.  Test-retest reliability of fMRI verbal episodic memory paradigms in healthy older adults and in persons with mild cognitive impairment.

Authors:  Francis Clément; Sylvie Belleville
Journal:  Hum Brain Mapp       Date:  2009-12       Impact factor: 5.038

9.  Galantamine-induced improvements in cognitive function are not related to alterations in alpha(4)beta (2) nicotinic receptors in early Alzheimer's disease as measured in vivo by 2-[18F]fluoro-A-85380 PET.

Authors:  J R Ellis; P J Nathan; V L Villemagne; R S Mulligan; T Saunder; K Young; C L Smith; J Welch; M Woodward; K A Wesnes; G Savage; C C Rowe
Journal:  Psychopharmacology (Berl)       Date:  2008-10-24       Impact factor: 4.530

10.  Dynamics analysis of the hippocampal neuronal model subjected to cholinergic action related with Alzheimer's disease.

Authors:  PeiHao Jiang; XiaoLi Yang; ZhongKui Sun
Journal:  Cogn Neurodyn       Date:  2020-04-01       Impact factor: 5.082

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.